For: | Cho JH, Jin SY. Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea. World J Clin Cases 2022; 10(19): 6349-6359 [PMID: 35979311 DOI: 10.12998/wjcc.v10.i19.6349] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v10/i19/6349.htm |
Number | Citing Articles |
1 |
梅 韩. Study on the Helicobacter pylori Infection and the Correlation Study of Anxiety-Depression Condition. Advances in Clinical Medicine 2023; 13(08): 13671 doi: 10.12677/ACM.2023.1381910
|
2 |
Elias Kouroumalis, Ioannis Tsomidis, Argyro Voumvouraki. Helicobacter pylori and gastric cancer: a critical approach to who really needs eradication. Exploration of Digestive Diseases 2024; : 107 doi: 10.37349/edd.2024.00043
|
3 |
Taslima Zaman, Ahsanul Haq, Rahnuma Ahmad, Susmita Sinha, Kona Chowdhury, Sultana Parvin, Mostofa Imran, Zaman U Humayra, Santosh Kumar, Mainul Haque. The Role of Probiotics in the Eradication of Helicobacter pylori and Overall Impact on Management of Peptic Ulcer: A Study Involving Patients Undergoing Triple Therapy in Bangladesh. Cureus 2024; doi: 10.7759/cureus.56283
|
4 |
Song-Wei Wang, Fang-Jung Yu, Fu-Chen Kuo, Jiunn-Wei Wang, Yao-Kuang Wang, Yi-Hsun Chen, Wen-Hung Hsu, Chung-Jung Liu, Deng-Chyang Wu, Chao-Hung Kuo. Rescue therapy for refractoryHelicobacter pyloriinfection: current status and future concepts. Therapeutic Advances in Gastroenterology 2023; 16: 175628482311709 doi: 10.1177/17562848231170941
|
5 |
Yujie Cheng, Lin Yang, Si Xu, Chong Zhang. Vonoprazan is Not Inferior to Proton Pump Inhibitors in Bismuth-containing Quadruple Therapy for Helicobacter pylori Eradication. Journal of Clinical Gastroenterology 2024; doi: 10.1097/MCG.0000000000002001
|
6 |
György Miklós Buzás, Péter Birinyi. Newer, Older, and Alternative Agents for the Eradication of Helicobacter pylori Infection: A Narrative Review. Antibiotics 2023; 12(6): 946 doi: 10.3390/antibiotics12060946
|
7 |
Jun-Hyung Cho.
Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line
Helicobacter pylori
eradication: a real-world evidence study
. Expert Review of Anti-infective Therapy 2024; : 1 doi: 10.1080/14787210.2024.2329251
|
8 |
Lyudmila Boyanova, Petyo Hadzhiyski, Raina Gergova, Rumyana Markovska. Evolution of Helicobacter pylori Resistance to Antibiotics: A Topic of Increasing Concern. Antibiotics 2023; 12(2): 332 doi: 10.3390/antibiotics12020332
|
9 |
Yu-Hua Peng, Xue Feng, Zhong Zhou, Lei Yang, Yun-Fei Shi. <i>Helicobacter pylori</i> infection in Xinjiang Uyghur Autonomous Region: Prevalence and analysis of related factors. World Journal of Gastroenterology 2023; 29(43): 5834-5847 doi: 10.3748/wjg.v29.i43.5834
Abstract(215) |
Core Tip(178) |
Full Article(HTML)(907)
|
Full Article with Cover (PDF)-15604K(28)
|
Full Article (Word)-2630K(18)
|
Audio-730K(1)
|
Peer-Review Report-196K(20)
|
Answering Reviewers-108K(21)
|
Full Article (PDF)-9943K(67)
|
Full Article (XML)-137K(24)
|
Times Cited (1)
|
Total Visits (2813)
|
Open
|
10 |
Bao Le, Duy Thanh Do, Hien Minh Nguyen, Bich Hang Do, Huong Thuy Le. Preparation, Characterization, and Anti-Adhesive Activity of Sulfate Polysaccharide from Caulerpa lentillifera against Helicobacter pylori. Polymers 2022; 14(22): 4993 doi: 10.3390/polym14224993
|
11 |
Nur Izreena Ismail, Khairul Najmi Muhammad Nawawi, Deborah Chew Chia Hsin, Kok Wei Hao, Nik Ritza Kosai Nik Mahmood, Gary Lee Chong Chearn, Zhiqin Wong, Azmi Mohd Tamil, Hazel Joseph, Raja Affendi Raja Ali. Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double‐blind, placebo‐controlled trial. Helicobacter 2023; 28(6) doi: 10.1111/hel.13017
|
12 |
Raktim Swarnakar, Shiv Lal Yadav. “<i>Helicobacter pylori </i>treatment guideline: An Indian perspective”: Letter to the editor. World Journal of Clinical Cases 2022; 10(29): 10817-10819 doi: 10.12998/wjcc.v10.i29.10817
Abstract(408) |
Core Tip(531) |
Full Article(HTML)(3775)
|
Full Article (PDF)-1639K(196)
|
Full Article (Word)-102K(57)
|
Audio-604K(5)
|
Peer-Review Report-657K(30)
|
Answering Reviewers-142K(38)
|
Times Cited (0)
|
Total Visits (6796)
|
Open
|
13 |
Jing Li, Huiying Shi, Fang Zhou, Li Xie, Rong Lin. The Efficacy and Safety of Regimens for Helicobacter pylori Eradication Treatment in China. Journal of Clinical Gastroenterology 2024; 58(1): 12 doi: 10.1097/MCG.0000000000001902
|
14 |
Yanmeng Wang, Yiling Li, Yuehua Gong, Yuzhen Dong, Jing Sun, Moye Chen. Antibiotic resistance characteristics and risk factors analysis of Helicobacter pylori strains isolated from patients in Liaoning Province, an area in North China. PeerJ 2023; 11: e15268 doi: 10.7717/peerj.15268
|
15 |
Irina Medakina, Larisa Tsapkova, Vera Polyakova, Sergey Nikolaev, Tatyana Yanova, Natalia Dekhnich, Igor Khatkov, Dmitry Bordin, Natalia Bodunova. Helicobacter pylori Antibiotic Resistance: Molecular Basis and Diagnostic Methods. International Journal of Molecular Sciences 2023; 24(11): 9433 doi: 10.3390/ijms24119433
|
16 |
Elizabeth Garvey, Joanne Rhead, Suffi Suffian, Daniel Whiley, Farah Mahmood, Naveen Bakshi, Darren Letley, Jonathan White, John Atherton, Jody Anne Winter, Karen Robinson. High incidence of antibiotic resistance amongst isolates of Helicobacter pylori collected in Nottingham, UK, between 2001 and 2018.
Journal of Medical Microbiology
2023; 72(11) doi: 10.1099/jmm.0.001776
|
17 |
|
18 |
Valerie Josephine Dirjayanto, Jessica Audrey, Daniel Martin Simadibrata. Vonoprazan-amoxicillin dual regimen with <i>Saccharomyces boulardii</i> as a rescue therapy for <i>Helicobacter pylori</i>: Current perspectives and implications. World Journal of Gastroenterology 2024; 30(10): 1280-1286 doi: 10.3748/wjg.v30.i10.1280
Abstract(83) |
Core Tip(83) |
Full Article(HTML)(908)
|
Full Article with Cover (PDF)-823K(59)
|
Full Article (Word)-173K(0)
|
Audio-1404K(0)
|
Peer-Review Report-216K(11)
|
Answering Reviewers-96K(10)
|
Full Article (PDF)-570K(65)
|
Full Article (XML)-94K(10)
|
Times Cited (0)
|
Total Visits (1565)
|
Open
|
19 |
Theodore Rokkas, Konstantinos Ekmektzoglou.
Advances in the pharmacological and regulatory management of multidrug resistant
Helicobacter pylori
. Expert Review of Clinical Pharmacology 2023; 16(12): 1229 doi: 10.1080/17512433.2023.2282061
|